Literature DB >> 27886889

Update on Ocular Myasthenia Gravis.

Stacy V Smith1, Andrew G Lee2.   

Abstract

Ocular myasthenia gravis (OMG) is a localized form of myasthenia gravis in which autoantibodies directed against acetylcholine receptors block or destroy these receptors at the postsynaptic neuromuscular junction. The hallmark of OMG is a history of painless weakness or fatigability of the extraocular muscles and ptosis with normal pupillary function and visual acuity. Clinical, laboratory, electrophysiologic, and pharmacologic tests are available for diagnosis. Treatment can begin with symptom management; there is no cure. Prognosis is improved by use of immunomodulators. Despite advances in treatment, research is needed, especially in the areas of surgical intervention and medical therapy based on risk stratification. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmune disease; Diplopia; Myasthenia gravis; Neuromuscular junction disorder; Ophthalmoplegia; Ptosis; Weakness

Mesh:

Year:  2017        PMID: 27886889     DOI: 10.1016/j.ncl.2016.08.008

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  9 in total

Review 1.  Cataplexy and Its Mimics: Clinical Recognition and Management.

Authors:  Sigrid Pillen; Fabio Pizza; Karlien Dhondt; Thomas E Scammell; Sebastiaan Overeem
Journal:  Curr Treat Options Neurol       Date:  2017-06       Impact factor: 3.598

2.  Generalization after ocular onset in myasthenia gravis: a case series in Germany.

Authors:  Feng Li; Benjamin Hotter; Marc Swierzy; Mahmoud Ismail; Andreas Meisel; Jens-C Rückert
Journal:  J Neurol       Date:  2018-09-17       Impact factor: 4.849

3.  Ophthalmologic manifestations in myasthenia gravis: presentation and prognosis.

Authors:  Onur Akan; Leyla Baysal-Kirac
Journal:  Acta Neurol Belg       Date:  2021-01-04       Impact factor: 2.396

4.  Prognostic predictors of remission in ocular myasthenia after thymectomy.

Authors:  Xiang Liu; Wangyan Zhou; Jun Hu; Mingsong Hu; Wenkui Gao; Shan Zhang; Wei Zeng
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 2.895

Review 5.  Controversies in Ocular Myasthenia Gravis.

Authors:  Amelia Evoli; Raffaele Iorio
Journal:  Front Neurol       Date:  2020-11-30       Impact factor: 4.003

6.  Myasthenia gravis: MuSK MG, late-onset MG and ocular MG.

Authors:  Feza Deymeer
Journal:  Acta Myol       Date:  2020-12-01

Review 7.  Management of diplopia.

Authors:  Daniela Adriana Iliescu; Cristina Mihaela Timaru; Nicolae Alexe; Elena Gosav; Algerino De Simone; Mehdi Batras; Cornel Stefan
Journal:  Rom J Ophthalmol       Date:  2017 Jul-Sep

Review 8.  Ptosis in childhood: A clinical sign of several disorders: Case series reports and literature review.

Authors:  P Pavone; Sung Yoon Cho; A D Praticò; R Falsaperla; M Ruggieri; Dong-Kyu Jin
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

Review 9.  Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.

Authors:  Lin Zhou; Xin Wei
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.